Dual EGFR and PI3k/mTOR Targeting of Head and Neck Cancer in Combination With Radiation Therapy

Document Type

Article

Publication Date

9-2017

Abstract

Previous research has identified the PI3K/Akt/mTOR and the EGFR/Ras/Raf/MAPK as key pathways that are dysregulated in head and neck cancer (HNSCC). In this study we describe the use of two novel small molecular agents, Dacomitinib and Gedatolisib, in combination with radiation treatment (RT) to target EGFR and PI3K as novel clinical treatment strategy in a murine xenograft model of human HNSCC.

Comments

59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA, September 24-27, 2017.

Link to Full Text

Share

COinS